Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,666 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Emerging treatments in advanced urothelial cancer.
Alhalabi O, Campbell M, Shah A, Siefker-Radtke A, Gao J. Alhalabi O, et al. Among authors: shah a. Curr Opin Oncol. 2020 May;32(3):232-239. doi: 10.1097/CCO.0000000000000618. Curr Opin Oncol. 2020. PMID: 32209822 Review.
Managing seminomatous and nonseminomatous germ cell tumors.
Chahoud J, Zhang M, Shah A, Lin SH, Pisters LL, Tu SM. Chahoud J, et al. Among authors: shah a. Curr Opin Oncol. 2018 May;30(3):181-188. doi: 10.1097/CCO.0000000000000446. Curr Opin Oncol. 2018. PMID: 29538040 Review.
Targeting advanced urothelial carcinoma-developing strategies.
Alhalabi O, Rafei H, Shah A, Siefker-Radtke A, Campbell M, Gao J. Alhalabi O, et al. Among authors: shah a. Curr Opin Oncol. 2019 May;31(3):207-215. doi: 10.1097/CCO.0000000000000532. Curr Opin Oncol. 2019. PMID: 30844889 Free PMC article. Review.
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM. Shah AY, et al. Eur J Cancer. 2019 Jun;114:67-75. doi: 10.1016/j.ejca.2019.04.003. Epub 2019 May 7. Eur J Cancer. 2019. PMID: 31075726 Free PMC article.
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
Laccetti AL, Garmezy B, Xiao L, Economides M, Venkatesan A, Gao J, Jonasch E, Corn P, Zurita-Saavedra A, Brown LC, Kao C, Kinsey EN, Gupta RT, Harrison MR, Armstrong AJ, George DJ, Tannir N, Msaouel P, Shah A, Zhang T, Campbell MT. Laccetti AL, et al. Among authors: shah a. Cancer Med. 2021 Apr;10(7):2341-2349. doi: 10.1002/cam4.3812. Epub 2021 Mar 1. Cancer Med. 2021. PMID: 33650321 Free PMC article.
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators. Choueiri TK, et al. Among authors: shah ay. N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982. N Engl J Med. 2021. PMID: 33657295 Free PMC article. Clinical Trial.
Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.
Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Siddiqui BA, et al. Among authors: shah a. J Immunother Cancer. 2021 Jul;9(7):e002850. doi: 10.1136/jitc-2021-002850. J Immunother Cancer. 2021. PMID: 34326169 Free PMC article.
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials.
Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Alhalabi O, et al. Among authors: shah a. Clin Genitourin Cancer. 2022 Feb;20(1):e16-e24. doi: 10.1016/j.clgc.2021.07.004. Epub 2021 Jul 12. Clin Genitourin Cancer. 2022. PMID: 34362693
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Jonasch E, et al. N Engl J Med. 2021 Nov 25;385(22):2036-2046. doi: 10.1056/NEJMoa2103425. N Engl J Med. 2021. PMID: 34818478 Free PMC article. Clinical Trial.
12,666 results
You have reached the last available page of results. Please see the User Guide for more information.